Researchers led by a Yale University team have developed a new measure for neoadjuvant chemotherapy efficacy for use in preoperative breast cancer trials.
The new metric, known as the Treatment Efficacy Score (TES), can gauge the relative effectiveness of an experimental treatment over standard of care by assessing the distribution of the continuous residual cancer burden score — a precise measure of invasive cancer after neoadjuvant chemotherapy calculated by merging tumor size, cancer cellularity and lymph node involvement into one continuous score.
Before TES, the efficacy of two